藥明巨諾-B：2023年度報告

Futu NewsApr 25 18:21 ET · Announcements

Pharmaceutical Juno-B (02126) issued approximately 1.231 million shares under the share award scheme

Pharmaceutical Juno-B (02126) announced that on April 2, 2024, approximately 120 will be issued under the share award scheme...

Zhitong FinanceApr 2 07:37 ET

JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023

JW (Cayman) Therapeutics (HKG:2126) recorded a narrower attributable loss for the year ended Dec. 31, 2023, of 768 million yuan from 846.1 million yuan during the year-ago period, a Tuesday filing on

MT NewswiresMar 20 08:44 ET

Read the 2023 results of Mingjuno-B (02126): Revenue increased 19.3% year-on-year, gross sales margin increased to 50.7%

On March 20, Pharmaceutical Juno-B (02126) announced its annual results for the year ended December 31, 2023.

Zhitong FinanceMar 20 05:22 ET

JW THERAP-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND CHANGE IN USE OF NET PROCEEDS FROM LISTING

Futu NewsMar 20 04:34 ET · Announcements

Pharmaceutical Juno-B (02126.HK) held a board meeting on March 20 to consider and approve annual results

Gelonghui, March 8, 丨 Pharmaceutical Juno-B (02126.HK) announced that the company would like to hold a board meeting on March 20, 2024 (Wednesday) to (i) consider and approve the Group's audited consolidated results for the year ended 31 December 2023 and their release; (ii) the proposed final dividend (if any); and (iii) address any other matters.

Gelonghui FinanceMar 8 03:55 ET